Statistics from Altmetric.com
This randomised, double-blind, placebo-controlled study is one of the largest multicentre studies investigating whether ambrisentan (an endothelin A receptor antagonist) reduces the rate of idiopathic pulmonary fibrosis (IPF) progression.
The investigators compared ambrisentan (more commonly used in the treatment of pulmonary hypertension (PH)) with placebo on the basis of preclinical studies suggesting endothelin …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.